Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Marrow grafting has evolved from a last resort to a primary treatment for specific malignant conditions.
• Chemoradiotherapy followed by marrow grafting yields 10%-30% cure rates in acute leukemia patients resistant to chemotherapy.
• Transplantation in first remission for acute nonlymphoblastic leukemia in patients under 50 shows a 50% cure rate, with better outcomes in younger individuals.

Purpose of the Study:

• To review current research in marrow transplantation.
• To explore the expanding applications of marrow grafting in malignant and nonmalignant diseases.
• To provide a basis for expecting continued improvement in marrow transplantation outcomes.

Main Methods:

• Review of current research in marrow transplantation.
• Analysis of cure rates for acute leukemia treated with chemoradiotherapy and marrow grafting.
• Exploration of marrow grafting for diseases with steep dose-response curves and marrow toxicity limitations.

Main Results:

• Marrow grafting is increasingly the preferred therapy for select malignant diseases.
• Transplantation offers significant, though variable, cure rates for acute leukemia.
• Research indicates potential for improved outcomes through broader donor availability, including partially matched and unrelated donors.

Conclusions:

• Marrow grafting is a vital therapeutic modality for malignant diseases, with ongoing research enhancing its efficacy.
• The expansion of donor pools, including partially matched family and unrelated donors, will increase patient access to marrow transplantation.
• Marrow transplantation is proving effective for nonmalignant hematologic disorders such as immunodeficiency syndromes, aplastic anemia, and genetic blood disorders.